MesencHyal-T develops advanced cell therapies for bone regeneration using allogeneic mesenchymal stem cells and hyaluronic acid. Their AI-powered platform optimizes treatment for bone injuries and degenerative conditions, offering scalable, ready-to-use products for improved healing and patient quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Bone injuries and degenerative bone diseases present significant challenges in achieving complete and timely healing, impacting patient quality of life. Current treatment modalities often involve invasive procedures, long recovery times, and variable efficacy, creating a need for more effective regenerative solutions.
Solution
MesencHyal-T develops advanced cell therapies for bone regeneration, leveraging allogeneic mesenchymal stem cells combined with hyaluronic acid. Their AI-powered platform aims to optimize treatment outcomes for patients with bone injuries and degenerative conditions. The company focuses on providing scalable, ready-to-use therapeutic products designed for long-term efficacy and a robust regulatory profile. This approach seeks to improve healing processes and enhance the quality of life for individuals affected by bone pathologies.
Target Audience
The primary target audience includes orthopedic surgeons, regenerative medicine specialists, and healthcare institutions focused on bone repair and reconstruction.
Features
- Allogeneic mesenchymal stem cells sourced from umbilical cord tissue.
- Formulation incorporating hyaluronic acid for enhanced therapeutic properties.
- Ex vivo, scalable production process for consistent cell therapy manufacturing.
- AI-driven platform for predicting treatment outcomes and optimizing patient selection.
- Ready-to-use solution designed for direct clinical application without the need for a scaffold.
- Focus on long-term efficacy and a favorable regulatory and safety profile.
- Proprietary intellectual property with patent applications filed in Argentina and PCT.